Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Chief Operating Officer

On January 26, 2021, the Board of Directors of Adaptive Biotechnologies Corporation (the "Company") appointed Mark Adams as Chief Operating Officer of the Company, effective January 25, 2021. Dr. Adams, 53, joined the Company in April 2020 as Chief Technical Officer. Additional biographical information regarding Dr. Adams is set forth in the Company's definitive proxy statement filed on April 24, 2020, which is incorporated by reference herein.

Dr. Adams' annual salary will be increased to $430,000, and his fiscal year annual incentive opportunity will be equal to 50% of his base salary. As Chief Operating Officer, Dr. Adams is entitled to the severance benefits of an Executive Vice President under the Company's form of Executive Severance Agreement, and he may also participate in other standard Company benefit programs.

Departure of Executive Vice President, Operations and Program Management

On January 21, 2021, the Company and Nancy Hill agreed that her tenure as Company's Executive Vice President, Operations and Program Management will be terminated, effective March 2, 2021. Ms. Hill's termination is not the result of any material disagreement with the Company regarding its operations, policies, or practices.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses